Pharmaceuticals shield exports against tariffs, Italy achieves export growth against the trend
- Italian Foreign Minister Tajani stated on Tuesday that the pharmaceutical industry is the core driving force behind the country's exports. Despite facing Trump’s tariff rhetoric and two geopolitical conflicts, export performance has remained “remarkable and beyond expectations.”
- At the conference of the Rome Pharmaceutical Industrial Association, Tajani pointed out that Italy’s economy grew by 3.3% last year, and the preliminary data for early 2026 are also encouraging, with the pharmaceutical sector’s outstanding contribution playing a significant role.
- He emphasized that exports account for nearly 40% of Italy’s economic output and that the government must support this sector, which has achieved “world-class results,” including by reducing bureaucratic burdens and addressing payment cycle issues.
- According to data from Italy’s National Institute of Statistics, the country’s pharmaceutical exports to the United States soared by 54.1% last year. Against the backdrop of Trump’s tariff rhetoric, Italy was the only major EU country to achieve export growth to the US.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Elon Musk changes his stance! Tesla (TSLA.US) delays Cybertruck production halt to late summer 2027, just two days after suggesting “refund deposits”
Elon Musk stated that Cybertruck production will be extended until late summer 2027 to clear the order backlog, and Tesla's stock price rose by about 4%.
Japanese dovish policymaker urges "slow down": Price increases are not driven by demand, rate hikes may drag down the economy and inflation
Toichiro Asada, a member of the Bank of Japan's Policy Board, stated that the central bank needs to remain cautious and closely monitor the impact of rate hikes on the economy, as rising interest rates pose the risk of suppressing the inflation trend.
Don't Be Misled by "Instant Purchase, Instant Access": Pro Series Zero Wait Has Been the Norm for Years, UBS Maintains Apple (AAPL.US) Target Price at $340
The waiting time for iPhone 18 Pro is approaching zero, and Duo deliveries are scheduled until the end of January. UBS maintains its forecast for iPhone revenue in the December quarter at $95.1 billions, representing a year-on-year increase of 11.5%.
Crypto prices
More
